{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-212548","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.122373+00:00","generated_at":"2026-06-24T04:25:49.158491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuvation Bio Q2 net loss $34.9M; restructures with 35% workforce cut","bullets":["Cash, equivalents, marketable securities $703.8M as of June 30, 2022; runway through 2028.","R&D expense $28.9M (up 106% YoY), G&A $8.9M (up 39% YoY) on higher headcount and stock comp.","Phase 1 monotherapy dosing underway for BET inhibitor NUV-868 in advanced solid tumors.","Appointed Dr. David Liu as CMO (July) and Kerry Wentworth as CRO (May) to Executive Committee.","Restructuring announced Aug 1, reducing workforce by 35% to cut costs and align with re-prioritized pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-212548","json":"https://secwatch.observer/filing/0001193125-22-212548.json","markdown":"https://secwatch.observer/filing/0001193125-22-212548.md","text":"https://secwatch.observer/filing/0001193125-22-212548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/0001193125-22-212548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/d312793d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:25:49.158491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}